Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus lenalidomide in elderly untreated DLBCL
ChiCTR1900026380Phase 4Recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab and lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: overall survival. Started Oct 2019; status: recruiting.
02
Drugs
rituximablenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR1900026380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026380.